Quince Therapeutics is no longer the ataxia company that entered the year. After the pivotal NEAT study of encapsulated dexamethasone missed both its primary and its main secondary endpoint in late January, the South San Francisco issuer wound down that program, settled the European Investment Bank loan at a discount, and in May absorbed Orphai Therapeutics in a stock-for-stock merger financed by a specialist healthcare private placement. The operating story is now LAM-001, an inhaled once-daily formulation of rapamycin aimed at pulmonary hypertension tied to interstitial lung disease, bronchiolitis obliterans after transplant, and sarcoidosis-associated pulmonary hypertension. Legacy holders own a thin slice of the fully diluted register. The traded common is a junior stub sitting beneath a large Series C preferred layer.
The cash print looks generous until the capital structure is unpacked. Quarter-end cash sat at $116 million after the placement closed. Net proceeds from that raise were $104 million. Management states that cash funds operations through year-end 2028. The same quarterly filing still carries substantial-doubt going-concern language because the Series C certificate can force cash settlement at fair value if stockholders do not approve conversion and share delivery on time. Stockholders equity is a $35 million deficit, which triggered a late-August Nasdaq notice under the $10 million minimum-equity rule. A special meeting is scheduled for early October to approve the conversion, raise authorized shares, and clear a change-of-control listing path that contemplates a rename to IRulya Therapeutics and a move to the Capital Market.
What the tape is pricing is not a cash box. At a recent close near $29, the million-share common float capitalizes at about $30 million. That figure is less than a quarter of the cash and far below the $144 million Series C carrying amount. Conversion, if approved, lifts the share count to about twelve million and recasts the equity as a several-hundred-million-dollar claim on a single Phase Two inhaled mTOR program whose human evidence is a ten-patient open-label study. The debate is whether that recap vote simply ratifies a recapitalization the market already treats as done, or whether a failed vote turns the cash into a preferred settlement pool and leaves residual common with almost nothing.